Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Leukemia Care Clear all
Completed Phase 3 Interventional Results available

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

NCT01371656
View directory record Official record
Conditions
Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
levofloxacin
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
78
States / cities
Little Rock, Arkansas • Downey, California • Duarte, California + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 1 Interventional

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT03016377
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Interventions
iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

NCT04801797
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional

Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

NCT03568994
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atovaquone, Cytarabine, Daunorubicin, Etoposide, Gemtuzumab Ozogamicin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 20 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia

NCT02975869
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Standard Leukemia Care, Palliative Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Not yet recruiting Not applicable Interventional

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

NCT07516353
View directory record Official record
Conditions
Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma, Acute Lymphoblastic Leukemia ,Lymphomas
Interventions
my.naviGATE Digital Tool
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
15 Years to 24 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 3 Interventional Results available

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02013167
View directory record Official record
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Standard of Care Chemotherapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

NCT02719574
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
FT-2102 (olutasidenib), Azacitidine, Cytarabine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Not yet recruiting Not applicable Interventional

2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy

NCT07856758
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
CAR T cell therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nutrition and Body Composition in Acute Lymphoblastic Leukemia

NCT01317940
View directory record Official record
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Interventions
Vitamin D and Calcium Citrate
Dietary Supplement
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 29 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

NCT02275533
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

NCT02039726
View directory record Official record
Conditions
AML
Interventions
Quizartinib, Salvage Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
36
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

NCT00074737
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
cenersen, Idarubicin, Cytarabine
Drug
Lead sponsor
Eleos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
La Jolla, California • Miami, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

NCT04482894
View directory record Official record
Conditions
Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes
Interventions
Palliative Care Visits
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

NCT01471067
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions
Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 5:38 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

NCT04029038
View directory record Official record
Conditions
CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
Interventions
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
6 Months to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma

NCT03178617
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoblastic Lymphoma, Acute Leukemia
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
5 Years and older
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Not yet recruiting Phase 1 Interventional

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07737769
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

NCT06803745
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Lymphoma
Interventions
200 cGy or 400 cGy total body irradiation (TBI)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

NCT05963971
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
PEDALL, Standard of care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

NCT01397734
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Arsenic trioxide
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

NCT05155709
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
siremadlin, venetoclax, azacitidine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 5:38 PM EDT